HK inno.N Deal History & Licensing Activity
HK inno.N is a large pharma headquartered in South Korea. The company currently has 11 active clinical trials, primarily in Metabolic.
Deals (12mo)
2
Active Trials
11
Top Modality
N/A
Focus Area
Metabolic
HK inno.N Pipeline Focus
Therapeutic areas and modalities where HK inno.N is most active based on deal history and clinical trial data.
Therapeutic Areas
HK inno.N Strategic Signals
Key indicators of HK inno.N's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
HK inno.N Clinical Pipeline
HK inno.N has 11 active clinical trials across 6 development phases.
1
Phase 4
1
Not Applicable
1
Unknown
5
Phase 1
1
Phase 2
2
Phase 3
See How Your Asset Matches HK inno.N's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Metabolic assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About HK inno.N Licensing & Deal Activity
HK inno.N is a large pharma company based in South Korea that has been actively engaged in licensing transactions across the biopharma landscape.
Key therapeutic areas of focus for HK inno.N include Metabolic (3 deals and trials), Autoimmune (1 deal and trial), and Cardiovascular (1 deal and trial).
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for HK inno.N and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against HK inno.N's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.